<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289195</url>
  </required_header>
  <id_info>
    <org_study_id>17-390</org_study_id>
    <nct_id>NCT03289195</nct_id>
  </id_info>
  <brief_title>Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer</brief_title>
  <official_title>A Prospective Study To Evaluate The Accuracy Of Percutaneous Breast MRI Biopsy In Diagnosing A Pathologic Complete Response Following Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the ability of a breast MRI biopsy to accurately&#xD;
      diagnose a complete tumor response to the neoadjuvant chemotherapy (NAC) that the patient&#xD;
      just finished. Numerous studies have shown that MRI has the highest accuracy for diagnosing a&#xD;
      complete tumor response. The investigator wants to see if in a certain group of women who's&#xD;
      breast cancer is no longer visible on the post-treatment MRI that the biopsy specimens from a&#xD;
      MRI guided biopsy will accurately diagnose a complete tumor response to treatment which may&#xD;
      in the future make breast surgery unnecessary in some women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This prospective single institution pilot study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>estimate the negative predictive value (NPV) of a percutaneous MRI biopsy</measure>
    <time_frame>2 years</time_frame>
    <description>In this context NPV is defined as the number of true negatives (biopsy negative, i.e., no disease found on the percutaneous biopsy and pCR) divided by the number of all biopsy negatives. While NPV is of primary interest we will also estimate positive predictive value, sensitivity, and specificity of the biopsy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>MRI biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled will have had complete MR imaging response post Neoadjuvant Chemotherapy (NAC) and will undergo percutaneous MR guided biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Biopsy</intervention_name>
    <description>Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.</description>
    <arm_group_label>MRI biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women age 18 years or older&#xD;
&#xD;
          -  Confirmed histologic diagnosis of operable HER2 overexpressing (ER&lt;10%, PR&lt;10%, and&#xD;
             HER2 2+ or FISH amplified) OR triple negative (ER&lt;10%, PR&lt;10%, and HER2 0/1+ or&#xD;
             2+/FISH not amplified) OR ER positive invasive ductal or invasive lobular breast&#xD;
             cancer including MSKCC pathology confirmation&#xD;
&#xD;
          -  Operable breast cancer treated with NAC undergoing either breast conservation or total&#xD;
             Mastectomy who have had a post-NAC clinical bilateral breast MRI demonstrating a&#xD;
             complete imaging response, which is defined as no residual tumor enhancement.&#xD;
&#xD;
          -  No indication of distant metastases (M0)&#xD;
&#xD;
          -  Tumor site amenable to MRI guided biopsy as determined by the radiologist&#xD;
&#xD;
          -  Definitive surgery being performed at MSKCC within within 0-60 days of completing NAC&#xD;
&#xD;
          -  ECOG performance status score of 0 to â‰¤ 2 and or KPS performance status score of 80%&#xD;
             to 100%&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must not be pregnant.&#xD;
&#xD;
          -  Women must not be breastfeeding&#xD;
&#xD;
          -  Willing and able to provide informed consent and adhere to the study visit schedule&#xD;
             and plan as specified in this protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history and concurrent disease:&#xD;
&#xD;
               -  Prior history of treated breast cancer&#xD;
&#xD;
               -  Any underlying medical or psychiatric conditions, which in the opinion of the&#xD;
                  investigator, will make performing the study intervention hazardous or obscure&#xD;
                  the interpretation of the results&#xD;
&#xD;
          -  Prohibited Treatments and/or Therapies:&#xD;
&#xD;
               -  Prior history of breast cancer surgery and/or radiotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast Cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Sutton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Sutton, MD</last_name>
    <phone>646-888-5455</phone>
    <email>suttone@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmoud El-Tamer, MD</last_name>
    <phone>646-888-4755</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Consent only)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Sutton, MD</last_name>
      <phone>646-888-5455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Consent only)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Sutton, MD</last_name>
      <phone>646-888-5455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Consent only )</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Sutton, PhD</last_name>
      <phone>646-888-5455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Suffolk-Commack (Consent only)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Sutton, MD</last_name>
      <phone>646-888-5455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Sutton, MD</last_name>
      <phone>646-888-5455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Sutton, MD</last_name>
      <phone>646-888-5455</phone>
    </contact>
    <contact_backup>
      <last_name>Mahmoud El-Tamer</last_name>
      <phone>646-888-4755</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 19, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Biopsy</keyword>
  <keyword>17-390</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

